Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Neutral 0

Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow - StockStory

📅 Amgen (AMGN) is scheduled to announce Q1 earnings results tomorrow afternoon on Thursday.

💰 Last quarter, the company beat revenue expectations with $9.87 billion reported, an 8.6% year-over-year increase.

🚀 Full-year revenue guidance also surpassed analyst estimates during the previous strong quarter.

⏳ Current market expectations for this quarter include a more modest 4.3% year-over-year revenue growth.

📉 This projected growth represents a slowdown compared to the 10% increase recorded in Q1 last year.

🔍 Analysts have increasingly turned bullish, with majority of estimates revised upward over the last 30 days.

⚠️ Despite recent optimism, Amgen has missed Wall Street's revenue estimates multiple times over the past two years.

🏥 In the biotech peer segment, Incyte recently reported results exceeding estimates with 20.9% year-over-year sales growth.

📈 The broader biotechnology sector has seen positive investor sentiment, with share prices up 10.8% on average last month.

📉 Conversely, Amgen's stock is down 2.9% during the same period and currently trades at $338.80 per share.

🎯 The average analyst price target stands at $352.73, indicating potential upside if earnings meet expectations.

Bullish Signals
  • Amgen beat analysts' revenue expectations last quarter with revenues of $9.87 billion, representing an impressive 8.6% year-over-year increase.
  • The company provided full-year revenue guidance that exceeded analysts' expectations despite the market anticipating only a 4.3% growth.
  • Analysts covering Amgen have grown increasingly bullish, with the majority of revenue estimates seeing upward revisions over the last 30 days.
  • Amgen currently trades at $338.80, which is below its average analyst price target of $352.73, indicating positive upside potential ahead of earnings.
Risk Factors
  • Amgen is down 2.9% over the last month while its peers in the biotechnology segment have averaged a 10.8% gain, underperforming the broader industry trend.
  • The market expects Amgen's revenue growth to slow significantly from the 10% increase recorded last year to just 4.3% year on year this quarter.
  • Amgen has missed Wall Street's revenue estimates multiple times over the last two years, despite having beaten them in the most recent quarter.
  • Analysts have grown increasingly bullish with majority upward revisions over the last 30 days, which could lead to a harsh reality check if current earnings do not meet elevated expectations.
Full Analysis
Amgen (NASDAQ:AMGN) is scheduled to report its first-quarter earnings later this Thursday afternoon, with results that will likely influence investor sentiment in the biotechnology sector. The company previously demonstrated strong performance by beating analysts' revenue expectations, recording revenues of $9.87 billion, which represented an 8.6% year-over-year increase. This marked a significant quarter for Amgen, as it not only exceeded immediate earnings estimates but also provided full-year revenue guidance that surpassed Wall Street's forecasts. Heading into this latest report, market expectations have adjusted to anticipate a more moderate growth trajectory. Analysts currently expect Amgen's revenue to grow by 4.3% year over year, marking a slowdown compared to the 10% increase recorded in the same quarter last year. Despite Amgen having missed Wall Street's revenue estimates multiple times over the past two years, sentiment from analysts covering the stock has recently shifted toward being increasingly bullish, with majority of revenue estimates seeing upward revisions over the last 30 days. Contextualizing Amgen’s performance against peers and broader market trends shows a positive undercurrent in biotechnology. Only Incyte has reported results this period so far, surpassing analyst revenue estimates with year-on-year sales growth of 20.9%. The overall biotechnology segment is experiencing positive investor sentiment, with share prices up 10.8% on average over the past month. In contrast, Amgen has dipped 2.9% during the same timeframe and enters the earnings call with an average analyst price target of $352.73 against a current share price of $338.80, suggesting potential upside if results align with growing bullish expectations.